The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:2186 May 18, 2006 Number 20
NextNext

Trastuzumab Treatment in Breast Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Joensuu, H.
-PubMed Citation
To the Editor: Joensuu and colleagues (Feb. 23 issue)1 report the provocative finding that a short treatment with trastuzumab (for nine weeks) combined with chemotherapy is effective in the adjuvant treatment of HER2-positive breast cancer. At a median follow-up of three years, the effect on event-free survival was in the range of that reported with the administration of trastuzumab for a year after adjuvant chemotherapy.2,3 However, this study lacks a randomized comparison with established regimens; neither the regimen of vinorelbine followed by three cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) nor the docetaxel–FEC sequence can be considered "conventional" adjuvant . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.